Clinical trials: Diabetes Type I
Diabetes Mellitus, Type 1
Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System
This interventional device study aims to compare mainly standard Multiple Daily Injection (MDI) therapy vs. Accu-Chek® Solo Micropump System and investigates participant satisfaction.
- Trial name
- PRO Solo (NCT03478969)
- Testing
- Accu-Chek® Solo micropump system, mylife™ OmniPod® Insulin Management System, Multiple Daily Injections (MDI) therapy
- Where
- 21 sites in Austria, Germany and 2 more
- Volunteers
- 181 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
- Trial name
- NCT03445533
- Testing
- Ipilimumab, Tilsotolimod with Ipilimumab
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 481 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Diabetes Mellitus, Type 1
INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy
The aim of the project is to document the international routine practice in sensor usage in patients treated with sensor-augmented pump therapy and to assess which variables (e.g.
- Trial name
- NCT00790088
- Where
- 26 sites in Austria, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the safety of islet preparation, iset transplantation…
- Trial name
- NCT00679042
- Testing
- Islets of Langerhans transplantation
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- CellTrans Inc.
Diabetes Mellitus, Type 1
Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicentre study of 52 weeks treatment duration.
- Trial name
- NCT02284009
- Testing
- Albiglutide weekly injection, Insulin
- Where
- 32 sites in France, Germany and 3 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1, Type 1 Diabetes
"FEXIS": (Feasibility of an Extended Wear CSII Set in Participants With T1DM)
Over 1 million patients globally currently manage their Type 1 Diabetes mellitus using continuous subcutaneous insulin infusion with an infusion set that needs to be changed every 3 days.
- Conditions
- Diabetes Mellitus, Type 1, Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes Mellitus, Insulin-Dependent, 1
- Trial name
- FEXIS (NCT04503564)
- Testing
- coil-reinforced soft polymer indwelling cannula
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Capillary Biomedical, Inc.
Type 1 Diabetes
ADvanced Hybrid Closed Loop Study in Adult Population With Type 1 Diabetes
The purpose of this study evaluate the safety and efficacy of the Advanced Hybrid Closed Loop (AHCL) system in sub-optimally controlled patients with T1D, in comparison with Multiple Daily Injection (MDI) therapy with Flash…
- Trial name
- ADAPT (NCT04235504)
- Testing
- MDI, AHCL
- Where
- 14 sites in France, Germany and 1 more
- Volunteers
- 122 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
The primary purpose of participation in this study is to compare the safety and efficacy of different dosing schedules of LY2605541 and how different dosing schedules of LY2605541 affect Hemoglobin A1c (HbA1c).
- Trial name
- IMAGINE 7 (NCT01792284)
- Testing
- LY2605541, Insulin Lispro
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 212 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Type 2 Diabetes
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Trial name
- NCT05893797
- Testing
- Insulin Lispro, Tempo Smart Button, Dexcom G6 CGM
- Where
- 9 sites in France
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
This study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014, a new blood sugar lowering insulin, and its effect on blood sugar levels when it is delivered via an…
- Trial name
- NCT03056456
- Testing
- LY900014, Insulin Lispro (Humalog)
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in…
- Trial name
- NCT01194245
- Testing
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart
- Where
- 19 sites in United States
- Volunteers
- 135 people
- Sponsor
- Halozyme Therapeutics
Type 1 Diabetes Mellitus
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting…
- Trial name
- NCT04476472
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Insulet Corporation
Chronic Kidney Disease, Type 1 Diabetes Mellitus
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes.
- Trial name
- FINE-ONE (NCT05901831)
- Testing
- Finerenone
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 242 people
- Sponsor
- Bayer
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)
Primary Objective: To evaluate the effect of virtual approach via novel technologies versus traditional study conduct on glycemic control in terms of glycated hemoglobin (HbA1c).
- Trial name
- NCT03260868
- Testing
- Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
- Where
- 6 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of TI Inhalation Power in combination with a basal insulin versus insulin aspart in combination with a basal insulin
- Trial name
- NCT01445951
- Testing
- Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin
- Where
- 90 sites in United States, Brazil and 2 more
- Volunteers
- 518 people
- Sponsor
- Mannkind Corporation
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
Type 1 Diabetes Mellitus
Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects
The study was a Phase 2, multicounty, multicenter, non-confirmatory, investigator- and subject masked, randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CFZ533 on…
- Trial name
- CCFZ533X2207 (NCT04129528)
- Testing
- CFZ533
- Where
- 12 sites in Belgium, Germany and 4 more
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus
Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
The objective of DIAGNODE-2 is to evaluate the efficacy of Diamyd compared to Placebo, upon administration directly into a lymph node in combination with an oral vitamin D/Placebo regimen, in terms of preserving endogenous…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Autoimmune Diseases, Metabolic Disease
- Trial name
- NCT03345004
- Testing
- Diamyd, Vitamin D
- Where
- 18 sites in Czechia, Netherlands and 2 more
- Volunteers
- 109 people
- Sponsor
- Diamyd Medical AB